Výsledky vyhledávání - "Deepak Lokwani"

Potential Technologies to Develop Cellulose Beads and Microspheres

Autor: Prakash N. Kendre, Deepak Lokwani, Ajinkya Pote, Sudarshan Singh, Titilope J. Jayeoye, Bhupendra G. Prajapati

Publikováno v: Regenerated Cellulose and Composites ISBN: 9789819916542

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12f4e8ad4e3f5b3c7815dedab9128c01
https://doi.org/10.1007/978-981-99-1655-9_6

Zobrazit plný text záznamu

Molecular hybridization-based design, PASE three-component synthesis, antiproliferative activity and molecular modelling studies of N,N-dimethylaminophenyl substituted 5H-chromeno[2,3-b]pyridine analogs

Autor: Pedavenkatagari Narayana Reddy, Nissi Sharon, Pannala Padmaja, Vinod G. Ugale, Deepak Lokwani, Shirish jain, Pragati P, Anjali K

Publikováno v: Journal of Molecular Structure. 1286:135589

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd2e1b559e908d31426a8d280fdb2b4c
https://doi.org/10.1016/j.molstruc.2023.135589

Zobrazit plný text záznamu

Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib's Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach

Autor: Sanjay J. Surana, Deepak Lokwani, Rahul Pawara, Iqrar Ahmad, Harsha Jadhav, Harun M. Patel

Publikováno v: Combinatorial chemistryhigh throughput screening. 25(1)

Background: Lung cancer has become the prominent cause of the cancer-related deaths globally. More than 80 % of all lung cancers have been diagnosed with Non- Small Cell Lung Cancer (NSCLC). The USFDA approved osimertinib to treat patients with metas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41057bb140255ba6fe565cf928799d86
https://pubmed.ncbi.nlm.nih.gov/33280593

Zobrazit plný text záznamu

BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC)

Autor: Harun M. Patel, Deepak Lokwani, Matin Shaikh, Sanjay J. Surana, Iqrar Ahmad

Third generation EGFR inhibitor osimertinib was approved as the first-line treatment for EGFR T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC) patients in 2017. However, EGFR tertiary Cys797 to Ser797 (C797S) point mutation emanate rapidly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d69450700ccc1396bdf14752357b02

Zobrazit plný text záznamu

Design of new chemicals entities as selective COX-2 inhibitors using structure optimization by molecular modeling studies

Autor: Bhandari, S., Bothara, K., Pawar, V., Dr. Deepak Lokwani, Devale, T.

Publikováno v: Scopus-Elsevier

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::47dd7e845ee7a7bd0c8c51f93bd57480
http://www.scopus.com/inward/record.url?eid=2-s2.0-84860893027&partnerID=MN8TOARS

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání